Therapy May Stem Spontaneous Bleeding Episodes, Mortality Rates The U.S. Food and Drug Administration (FDA) has approved Octapharma USA’s Investigational New Drug Application for octaplex® (Human Prothrombin Complex,...
Octapharma Clinical Trial Begins in the US and Germany Treating Hemophilia A Patients with First Recombinant Factor VIII Derived from a Human Cell-Line
Multi-Center Study Investigates Prospects of Improved Safety, Immunogenicity
Octapharma has notified the Plasma Protein Therapeutics Association that it is terminating its Global Membership and Regional Membership in the organization.
Lachen, Switzerland, (24 Sept 2010) – Octapharma AG today announced the publication of the recently concluded octagam®10% study in the indication Immune Thrombocytopenic Purpura (ITP) in the scientific journal “Hematology”.
Urgent: Voluntary market withdrawal - September 24, 2010 octagam (Immune Globuline Intravenous (human) 5% Liquid Preparation)
Dear Healthcare Professional On August 20, 2010, in the interest of patient safety, Octapharma USA Inc. initiated a voluntary market withdrawal of selected lots of octagam® [Immune Globulin Intravenous (human)] 5% Liquid...
Update: Product Withdrawal/Product Recall - octagam (octagam 50mg/ml) and octagam 10% (octagam 100mg/ml)
In response to current measures taken related to the recent increase in the reporting frequency of thromboembolic events (TEEs) in connection with octagam® (human normal immunoglobulin for i.v. administration, 50 mg/ml),...
The Next-Generation VWF/FVIII Concentrate, Wilate®, Strives to Reflect the Normal Physiological Condition
World Haemophilia Experts Present Octapharma's Newest Product Specifically Developed for Patients with von Willebrand Disease